Arylsulfonanilide ureas
AssigneeTularik Inc.
InventorJonathan B. Houze
Life of this patent
Estimating the term…
Abstract
The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
Claims33
A compound having the formula:
- or a pharmaceutically acceptable salt thereof, wherein
- X is a member selected from the group consisting of O, S and NH;
- R1 and R2 are each members independently selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl;
- R3 is a member selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl, or is combined with Y and the nitrogen atom to which each is attached to form a 5-, 6- or 7-membered heterocyclic ring;
- R4 is a member selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, —OR11, —SR11 and —NR11R12, wherein R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C8)alkyl and (C1-C8)heteroalkyl;
- Y is a member selected from the group consisting of a heterocyclic ring, heterocyclyl(C1-C4)alkyl and heterocyclyl(C1-C4)heteroalkyl, or is optionally linked together with R3 to form a 5-, 6- or 7-membered heterocyclic ring;
- and
- Ar is a member selected from the group consisting of:
- wherein
- X1 and X2 are each independently selected from the group consisting of F, Cl and Br.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
- or a pharmaceutically acceptable salt thereof, wherein
- X is a member selected from the group consisting of O, S and NH;
- R1 and R2 are each members independently selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl;
- R3 is a member selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl, or is combined with Y and the nitrogen atom to which each is attached to form a 5-, 6- or 7-membered heterocyclic ring;
- R4 is a member selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, —OR11, —SR11 and —NR11R12, wherein R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C8)alkyl and (C1-C8)heteroalkyl;
- Y is a member selected from the group consisting of a heterocyclic ring, heterocyclyl(C1-C4)alkyl and heterocyclyl(C1-C4)heteroalkyl, or is optionally linked together with R3 to form a 5-, 6- or 7-membered heterocyclic ring;
- and
- Ar is a member selected from the group consisting of:
- wherein
- X1 and X2 are each independently selected from the group consisting ofF, Cl and Br.
A method of treating or preventing a disease state characterized by abnormally high levels of low density lipoprotein particles or cholesterol in the blood, or by an abnormally high level of cell proliferation, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising a compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein
- X is a member selected from the group consisting of O, S and NH;
- R1 and R2 are each members independently selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl;
- R3 is a member selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl, or is combined with Y and the nitrogen atom to which each is attached to form a 5-, 6- or 7-membered heterocyclic ring;
- R4 is a member selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, —OR11, —SR11 and —NR11R12, wherein R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C8)alkyl and (C1-C8)heteroalkyl;
- Y is a member selected from the group consisting of a heterocyclic ring, heterocyclyl(C1-C4)alkyl and heterocyclyl(C1-C4)heteroalkyl, or is optionally linked together with R3 to form a 5-, 6- or 7-membered heterocyclic ring;
- and
- Ar is a member selected from the group consisting of:
- wherein
- X1 and X2 are each independently selected from the group consisting of F, Cl and Br.
Dependencies are inferred from the claim text.